Drug Profile
Research programme: opioid analgesics - Antares
Alternative Names: AP-159 - AntaresLatest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator Antares Pharma
- Class Pyridines
- Mechanism of Action Opioid receptor agonists; Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 24 May 2022 Antares Pharma has been acquired by Halozyme Therapeutics
- 12 Oct 2007 Antares Pharma signs development and licensing agreement with undisclosed pharmaceutical company for transmucosal opioid analgesic product
- 29 Nov 2006 Preclinical trials in Pain in USA (PO)